Not just a prostate: problems of benign prostatic hyperplasia in elderly


如何引用文章

全文:

详细

Benign prostatic hypertrophy (BPH) is the main disease which determines the quality of life of the ald men. The article includes literature and own data, confirming the high prevalence of it in men alder then 60-70. It is underlined that because of lots of reasons BHP often can be found only on autopsy. The article describes the link between BPH with cardiovascular and cerebrovascular diseases, diabetes and metabolic syndrome, and the common features of its pathogenesis, particular atherosclerosis. The questions of BPH diagnostics in old patients are discussed. It is underlined that heavy complications of the disease, symptoms and in some degree therapy lead to decreasing of old patient's quality of life, what make BPH one of the main problems of BPH in general somatic practice.

参考

  1. Лопаткин Н.А., Сивков А.В. Доброкачественная гиперплазия предстательной железы. М., 1999. С. 99-102.
  2. Вишневский Е.Л., Лоран О.Б., Сухоруков В.С. и др. Влияние кардуры (доксазозина) на полисистемный энергетический метаболизм у больных доброкачественной гиперплазией простаты // Андрология. 2001. № 4. С. 88-92.
  3. Berry SJ, Coffey DS, Walsh PC, et al. The development or human benign prostatic hyperplasia with age. J Urol 1984;132:474-79.
  4. Logie JW, Clifford GM, et al. Lower urinary tract symptoms suggestive of benign prostatic obstruction - Triumph: the role of general practice databases. Eur Urol 2001;39(Suppl. 3):42-47.
  5. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150:85-89.
  6. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-71.
  7. Bartsch G, MЯller HR, Oberholzer M, et al. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979;122:487-91.
  8. Furuya S, Kumamoto Y, Yokoyama E, et al. Alpha-Adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982;128:836-39.
  9. Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998;159:1810-15.
  10. Montorsi F, Moncada I. Safety and tolerability of treatment for BPH. Eur Urol 2006;5(Suppl.):1005.
  11. Barendrecht MM, Koopmans RP, et al. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: cardiovascular system. BJU Int 2005;95:19-28.
  12. Djavan B, Chaple C, Milani S, et al. State of the art on the efficacy and tolerability of alpha-adrenoreceptor antagonists in patients with low urinary tract symptoms suggestive of benign hyperplasia. Urology 2004;64:1081-88.
  13. Buzelin JM, Fonteyne E, Kontturi M, et al. Comparison of tamsulosin with alfuzosin in the treatment of patient with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign hyperplasia). The European Tamsulosin Study Group. Br J Urology 1997;80:597-605.
  14. Koff W, Bertero E, Pinheiro G, et al. A randomized, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia. Program and abstracts of the American Urological Association Annual Meeting. May 21-26. 2005. San Antonio, Texas. Abstract 1643.
  15. Hellstrom W, Smith W, Sikka C. Effects of alpha-blockers on ejaculatory function in normal subjects. Program and abstracts of the American Urological Association Annual Meeting. May 21-26. 2005. San Antonio, Texas. Abstract 874.
  16. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfusozin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double- blind, placebo-controlled stadies. BJU Int 2003;92:257-61.
  17. Hofner K, Claes H, De Reijke TM, et al. Tamsulosin 0,4 mg once daily: effect on sexual function in patints with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:335-41.
  18. Debruyne F, Barkin J, van Erps PV, et al. Efficacy and safety of longterm treatment with the dual 5б-reductase inhibitir dutasteride in men with symptomatic benign hyperplasia. Eur Urol 2004;46:488-95.
  19. Roehorborn CG, Lee M, Meehan A. PLESS Study Groupe. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology 2003;62:894-99.
  20. Controlled Clinical Trials the MTOPS. Elsevier science 24. 2003:224-43.
  21. Barkin J, Guimaraes M, Jacobi G, et al, on behalf of the SMART-1 Investigator Groupe. Alfa-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5б-reductase inhibitor dutasteride. Eur Urol 2003;44:461-66.
  22. The 5th International Consultation on BHP Proceedings. 2001.
  23. Marks LS. Preventing BPH Disease in asimptomatic Men at risk of progression. UAU. April/May 2006.
  24. Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol 2004;45(4):411-19.
  25. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2309&mid=1085056570&magid=173

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##